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ABSTRACT
Introduction: Controlled clinical studies have
shown that the efficacy of tocilizumab (TCZ)
monotherapy is superior to that of tumor
necrosis factor inhibitor (TNFi) monotherapy
and comparable to that of TCZ plus
methotrexate (MTX) for the treatment of
rheumatoid arthritis (RA). This study compared
the real-world effectiveness of TCZ monother-
apy vs. TNFis plus MTX in US patients with RA.
Methods: TCZ-naı¨ve patients from the Corrona
RA registry with prior exposure to C 1 TNFi who
initiated TCZ monotherapy or TNFi ? MTX
were included. Outcomes included mean
change in Clinical Disease Activity Index
(CDAI), achievement of low disease activity
(LDA; CDAI B 10), achievement of modified
American College of Rheumatology (mACR)
20/50 responses, and mean change in modified
Health Assessment Questionnaire (mHAQ) at
6 months. Patients initiating TNFi ? MTX were
grouped by MTX dose (B 10 mg;[10
to B 15 mg;[ 15 to B 20 mg;[ 20 mg); out-
comes in each group were compared with TCZ
monotherapy using trimmed populations (ex-
cluding patients outside the propensity score
distribution overlap).
Results: Patients in all groups experienced
improvement in CDAI at 6 months (mean
change, - 6.9 to - 9.7), with no significant
differences between the TCZ monotherapy and
TNFi ? MTX groups. Achievement of LDA and
mACR responses at 6 months were comparable
between the TCZ monotherapy and TNFi ?
MTX groups; overall, 26.8–38.0% of patients
achieved LDA, 24.3–37.6% achieved mACR20
response and 13.2–20.8% achieved mACR50
response. The mean change in mHAQ at
6 months was - 0.1 in all groups.
Conclusions: In this real-world population of
US patients with RA who had prior TNFi expo-
sure, there was no evidence of a difference in
the effectiveness of TCZ monotherapy com-
pared with that of TNFi ? MTX, regardless of
MTX dose, at 6 months for improving RA dis-
ease activity.
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PLAIN LANGUAGE SUMMARY
Tumor necrosis factor inhibitors (TNFis) are
often the first choice for biologic therapy in
patients with rheumatoid arthritis (RA). How-
ever, up to 40% of patients may have an inad-
equate response to a TNFi; these patients may
switch to a different TNFi or to a biologic with
an alternative mechanism of action (MOA).
Currently, limited and conflicting information
is available regarding the benefits of switching
to a biologic with an alternative MOA vs. a
second TNFi. Comparative effectiveness studies
of TNFis vs. non-TNFi biologics are needed to
ensure the best clinical outcomes in patients
with inadequate responses to TNFis.
Tocilizumab (TCZ) is an interleukin-6 recep-
tor inhibitor approved for the treatment of
moderate to severe RA. Whereas TNFis generally
have increased efficacy when administered with
methotrexate (MTX), TCZ has similar efficacy
when administered as monotherapy or in
combination with MTX. This study compared
the effectiveness of TCZ monotherapy with that
of TNFis plus varying dose ranges of MTX in
patients with RA and prior treatment with 1 or
more TNFi in routine US clinical practice.
Patients treated with TCZ monotherapy or a
TNFi with MTX experienced substantial and
comparable improvement in RA disease activity
at 6 months. There was no evidence of a dif-
ference in the effectiveness of TCZ monother-
apy compared with TNFi with MTX, regardless
of MTX dose, for improving RA disease activity
in patients with prior TNFi exposure. These
results can help guide decision-making when
selecting a biologic therapy for patients with RA
who were previously treated with TNFis.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic
autoimmune disorder characterized by joint
inflammation that can result in pain, joint
deformity, functional disability, and decreased
health-related quality of life [1–3]. The goal of
treatment in patients with RA is to reduce dis-
ease activity and improve patients’ clinical
outcomes and quality of life. Current treatment
guidelines recommend conventional synthetic
disease-modifying antirheumatic drugs
(csDMARDs), such as methotrexate (MTX), as
first-line therapy, followed by addition of
another csDMARD or a biologic therapy in
patients with an inadequate response [4].
The first choice of biologic therapy is typi-
cally a tumor necrosis factor inhibitor (TNFi).
Although TNFis are associated with improve-
ment in the signs and symptoms of RA, 30–40%
of patients may have an inadequate response to
a TNFi due to primary lack of response or sec-
ondary treatment failure due to resistance or
intolerance [5–8]. Patients with an inadequate
response to a TNFi may switch to a different
TNFi or to a biologic with an alternative
mechanism of action (MOA) [4].
Limited and conflicting data are available
regarding the benefits of switching to a biologic
with an alternative MOA vs. a second TNFi in
patients with RA. Observational studies con-
ducted in Europe demonstrated that switching
to rituximab was more effective than switching
to a subsequent TNFi in patients with an inad-
equate response to 1 or more TNFi [9–11].
However, an observational study of US patients
with RA showed similar improvement in disease
activity between patients who switched to
abatacept and those who switched to a subse-
quent TNFi [12]. In a multicenter, randomized
controlled trial in France, a higher proportion of
patients with an inadequate response to their
first TNFi who switched to a biologic with a
different MOA achieved low disease activity
(LDA) at 24 and 52 weeks compared with those
who switched to a second TNFi [13].
Tocilizumab (TCZ) is a monoclonal antibody
that blocks the interleukin-6 receptor and is
approved for the treatment of patients with
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moderate to severe RA who have had an inad-
equate response to 1 or more DMARD [14]. TCZ
can be administered as monotherapy or in
conjunction with MTX or other csDMARDs
[14]. Whereas TNFis generally have increased
efficacy when administered with concomitant
MTX, clinical studies have shown that TCZ has
similar efficacy when administered as
monotherapy or in combination with
csDMARDs [15, 16]. TCZ monotherapy may
therefore be an effective treatment option for
patients who cannot tolerate or prefer not to use
MTX.
Currently, real-world studies comparing the
effectiveness of TCZ monotherapy to TNFis ?
MTX in US patients with RA are lacking. The
objective of this study was to compare the
effectiveness of TCZ monotherapy with that of
TNFis plus varying dose ranges of MTX in
patients with RA and prior exposure to 1 or
more TNFi in routine clinical practice in the
United States.
METHODS
Study Setting
The Corrona registry has been previously
described in detail [17, 18]. Briefly, the Corrona
RA registry (NCT01402661) is an independent,
prospective observational cohort that collects
longitudinal real-world data from patients and
their treating rheumatologists [17, 19]. The
registry includes patients recruited by 686 par-
ticipating rheumatologists from 174 private and
academic practice sites across 41 states in the
United States. As of March 31, 2018, data on
48,535 patients with RA have been collected.
Corrona’s database currently includes informa-
tion from 367,457 patient visits and 169,968
patient-years of follow-up observation, with a
mean duration of patient follow-up of
4.30 years (median, 3.35 years).
The study was conducted according to the
current (2013) version of the Declaration of
Helsinki. Ethics approvals for this study were
obtained from a central institutional review
board (New England Independent Review
Board, IRB# 120160610). For academic
investigative sites that did not receive a waiver
to use the central IRB, full board approval was
obtained from the respective governing IRBs
and documentation of approval was submitted
to the Sponsor prior to initiating any study
procedures.
Study Population and Data Collection
Eligible participants were TCZ-naı¨ve patients
with RA in the Corrona registry with prior use
of C 1 TNFi who initiated TCZ as monotherapy
or a TNFi ? MTX (without another csDMARD)
between January 2010 and October 2015.
Patients in LDA or remission as assessed by
Clinical Disease Activity Index (CDAI; B 10)
were excluded. Patients must have had a follow-
up visit 6 months after initiation with CDAI
data available at baseline and follow-up; due to
the observational nature of the study, the
6-month visit may have occurred in a window
of 3–9 months. For patients with more than 1
visit within the 3- to 9-month window, the visit
closest to 6 months was designated as the
6-month follow-up visit. For patients who ini-
tiated TCZ monotherapy or a TNFi ? MTX
between Corrona visits, demographic and clin-
ical characteristics from the visit prior to initi-
ation were used as baseline characteristics,
provided the prior visit was B 4 months before
initiation. Patients who initiated a TNFi ? MTX
must have had MTX dose information available
at baseline. If patients had more than 1 eligible
initiation of TNFi ? MTX, only the first initia-
tion was included in the analysis. For patients
who had an eligible TNFi ? MTX initiation and
an eligible TCZ initiation during the study per-
iod, only the TNFi ? MTX initiation was
included due to sample size considerations.
Data from Corrona were collected from
physician and patient questionnaires com-
pleted during routine clinical encounters that
occurred over the 6-month study period. Data
recorded at the time of clinical encounter
included use of csDMARDs and biologics;
28-joint tender and swollen counts; CDAI;
modified Health Assessment Questionnaire
(mHAQ); physician and patient assessments of
global disease activity; patient assessment of
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pain; and American College of Rheumatology
(ACR) functional status. Data on demographics,
insurance status, comorbid conditions, physi-
cian and patient reported RA disease character-
istics, and RA medications were available
for C 95% of patients.
Drug Exposure Cohorts
Patients who initiated a TNFi ? MTX were
grouped into four cohorts by weekly
MTX dose: B 10 mg;[ 10 to B 15 mg;[15
to B 20 mg; and[ 20 mg. To balance for pre-
disposing factors that may increase a patient’s
likelihood of receiving either TCZ monotherapy
or a TNFi ? MTX, a propensity score (PS)
[20, 21]—or the probability of treatment selec-
tion—was calculated for each eligible patient
using baseline (at the time of drug initiation)
patient demographics (age, sex, race, body mass
index, smoking status, and work status), disease
characteristics (duration of RA, ACR functional
class, mHAQ, CDAI, and patient pain scores),
and treatment history (prednisone use/dose and
prior biologic use). Outcomes in patients
receiving TCZ monotherapy and each TNFi ?
MTX group were compared in trimmed popu-
lations excluding patients outside the PS distri-
bution overlap.
For sensitivity analyses, outcomes were
compared between stratified-matched popula-
tions. Patients in the TCZ monotherapy group
and each TNFi ? MTX group were stratified by
prior treatment with 1 vs. C 2 prior TNFi and
matched based on the PS using a caliper (max-
imum difference in propensity) of 0.02. The
TCZ monotherapy group was matched sepa-
rately with each TNFi ? MTX group; i.e., the
same group of patients receiving TCZ
monotherapy were matched to each TNFi ?
MTX group.
Study Outcomes
The primary outcome was mean change from
baseline in CDAI at 6 months. Secondary out-
comes included the proportion of patients who
achieved LDA (CDAI B 10), the proportion of
patients who achieved 20% or 50%
improvement in modified ACR response criteria
(mACR20 or mACR50, respectively) [22], and
mean change from baseline in mHAQ at
6 months.
Statistical Analysis
All statistical analyses were performed using
Stata version 14 (StataCorp LLC). Baseline
characteristics were compared between the TCZ
monotherapy and TNFi ? MTX groups using
standardized differences. Standardized differ-
ences provide a measure of clinically important
differences, even if there are no statistically
significant differences. A standardized differ-
ence\ 0.1 has been taken to indicate a negli-
gible difference in the mean or prevalence of a
covariate between treatment groups [20].
Patients were included regardless of switch-
ing or discontinuation of the initial biologic.
For patients who discontinued their initial
therapy prior to the 6-month follow-up visit but
did not switch to another biologic, the out-
comes at the 6-month visit were used for anal-
yses. For patients who switched biologics prior
to the 6-month follow-up visit, continuous
outcomes (mean changes in CDAI and mHAQ)
were assessed using last observation on drug
carried forward and binary outcomes (achieve-
ment of LDA and mACR 20/50 responses) were
assessed by nonresponse imputation.
Outcomes were analyzed in the trimmed
populations by random effects (adjusted for
clustering by site) linear models for continuous
outcomes and random effects logistic regression
models for binary outcomes. For continuous
outcomes, the effect of TCZ monotherapy vs.
each TNFi ? MTX dose group was assessed by
an estimated beta coefficient from the linear
regression model representing the difference in
mean outcomes between the groups. For binary
outcomes, the effect of TCZ monotherapy vs.
each TNFi ? MTX dose group was assessed by
an estimated odds ratio (OR) representing the
increase or decrease in odds of the outcome. In
multivariable adjusted models, outcomes were
analyzed using multivariable models adjusting
for the covariates included in the PS to account
for remaining imbalances among the trimmed
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populations; 95% confidence intervals were
estimated for each effect. For the matched
analyses, estimated differences or odds ratios
were calculated adjusting for clustering on the
matched pairs with 95% confidence intervals
for each effect. As an additional sensitivity
analysis, outcomes in the matched pairs were
analyzed using multivariable adjusted models
with 95% confidence intervals for each effect.
RESULTS
Patient Demographics and Baseline
Clinical Characteristics
A total of 301 patients who initiated TCZ
monotherapy and 772 patients who initiated a
TNFi ? MTX met the inclusion criteria prior to
implementation of the PS (Fig. 1). Among the
TNFi ? MTX initiators, 116 initiated with
MTX B 10 mg, 200 with MTX[10 to B 15 mg,
337 with MTX[ 15 to B 20 mg and 119 with
MTX[ 20 mg. Among the patients treated with
TCZ monotherapy, 96% were receiving TCZ
intravenously every 4 weeks; of the 4% of
patients (n = 12) receiving TCZ subcutaneously,
seven patients received doses every 2 weeks,
three received doses every week, and two had
missing dose information. Patient demograph-
ics and baseline characteristics of the untrim-
med population are described in Supplementary
Table 1.
After excluding patients outside the PS dis-
tribution overlap and restricting the data to
unique initiations per patient, the four trimmed
cohorts included 283 TCZ monotherapy initia-
tors vs. 108 TNFi ? MTX B 10 mg; 300 TCZ
monotherapy initiators vs. 186 TNFi ? MTX[
10 to B 15 mg; 292 TCZ monotherapy initia-
tors vs. 273 TNFi ? MTX[ 15 to B 20 mg; and
285 TCZ monotherapy initiators vs. 107
TNFi ? MTX[ 20 mg. The stratified-matched
populations included 61 patients in each arm
receiving TCZ monotherapy vs.
TNFi ? MTX B 10 mg; 71 receiving TCZ
monotherapy vs. TNFi ? MTX[10
to B 15 mg; 95 receiving TCZ monotherapy vs.
TNFi ? MTX[ 15 to B 20 mg; and 53 receiving
TCZ monotherapy vs. TNFi ? MTX[20 mg.
Patient demographics and baseline charac-
teristics were generally comparable between the
TCZ monotherapy and TNFi ? MTX groups in
the trimmed cohorts (Table 1). Patients receiv-
ing TCZ monotherapy had significantly longer
disease duration than those who received TNFi
with one of the higher MTX doses ([15
to B 20 mg and[ 20 mg). Higher proportions
of patients receiving TCZ monotherapy had
received C 3 prior biologics and C 2 prior TNFi
than patients in all the TNFi ? MTX dose
groups. There were no significant differences in
patient demographics, baseline clinical charac-
teristics, or treatment history between the TCZ
monotherapy and TNFi ? MTX groups in the
stratified-matched populations (Supplementary
Table 2).
In the trimmed population, 70.0–71.6% of
patients in the TCZ monotherapy groups and
64.8–73.7% of patients in the TNFi ? MTX
groups were still receiving their initial biologic
at 6 months; 11.6–12.7% of patients in the TCZ
monotherapy groups and 9.7–16.7% of patients
in the TNFi ? MTX groups switched to a new
biologic, and 16.8–17.3% and 15.7–18.0%,
respectively, discontinued without switching
(Table 2). In the stratified-matched population,
63.9–77.4% of patients in the TCZ monother-
apy groups and 59.0–68.9% of patients in the
TNFi ? MTX groups were still receiving their
initial biologic at 6 months; 9.4–21.3% of
patients in the TCZ monotherapy groups and
11.3–16.8% of patients in the TNFi ? MTX
groups switched to a new biologic, and
8.5–16.8% and 18.9–24.2%, respectively, dis-
continued without switching (Table 2). No sig-
nificant differences were observed between the
TCZ monotherapy and TNFi ? MTX groups in
the rates of switching or discontinuation of the
initial biologic over the 6-month study period
(Table 2).
Outcomes at 6 Months
All treatment groups experienced improvement
from baseline in CDAI at 6 months (Supple-
mentary Table 3). Mean change from baseline
in CDAI ranged from - 6.9 to - 9.7 in the
trimmed population and from - 6.1 to - 9.9 in
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the stratified-matched population. In unad-
justed analyses in the trimmed population,
there were no significant differences in change
in CDAI at 6 months between patients who
received TCZ monotherapy and those who
received TNFi ? MTX, except MTX[15
to B 20 mg; however, there were no significant
differences after adjustment for covariates used
in the PS (Fig. 2) and no differences in unad-
justed or adjusted analyses of the stratified-
matched population (Fig. 2; Supplementary
Fig. 1).
Overall, 26.8–38.0% of patients in the trim-
med population and 20.8–38.0% in the strati-
fied-matched population achieved LDA at
6 months (Supplementary Table 3). There were
no significant differences in the likelihood of
achieving LDA at 6 months between patients
receiving TCZ monotherapy and any of the
TNFi ? MTX groups in unadjusted or adjusted
analyses of the trimmed or stratified-matched
populations (Fig. 3; Supplementary Fig. 2).
The proportions of patients with mACR20
response at 6 months ranged from 24.3 to
37.6% in the trimmed population and 22.1 to
37.1% in the stratified-matched population
(Supplementary Table 3). The proportions of
patients with mACR50 response at 6 months
ranged from 13.2 to 20.8% in the trimmed
population and 11.6 to 19.7% in the stratified-
matched population (Supplementary Table 3).
In the trimmed population, there were no
Fig. 1 Patient disposition. aThe 6-month follow-up visit
occurred in a window of 3–9 months. bOne initiation per
patient across both groups, with preference for keeping
TNFi initiation if feasible. CDAI, clinical disease activity
index; csDMARD, conventional synthetic disease-modify-
ing antirheumatic drug; MTX, methotrexate; TCZ,
tocilizumab; TNFi, tumor necrosis factor inhibitor
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significant differences in the likelihood of
achieving mACR20 or mACR50 responses at
6 months between patients receiving TCZ
monotherapy and those receiving TNFi ? MTX
in unadjusted or adjusted analyses, except
MTX[ 15 to B 20 mg (Fig. 4). In the stratified-
matched population, there were no significant
differences in the likelihood of achieving
mACR20 or mACR50 response between the TCZ
monotherapy and any TNFi ? MTX group in
unadjusted or adjusted analyses (Fig. 4; Supple-
mentary Fig. 3).
In the trimmed population, the mean
change from baseline in mHAQ at 6 months
was - 0.1 in all treatment groups; in the strati-
fied-matched population, the mean change
from baseline in mHAQ ranged from 0 to - 0.2
(Supplementary Table 3). There were no
significant differences in the mean change from
baseline in mHAQ at 6 months between the
TCZ monotherapy and TNFi ? MTX treatment
groups in unadjusted or adjusted analyses of the
trimmed or stratified-matched populations
(Fig. 5; Supplementary Fig. 4).
DISCUSSION
Using data from the US-based Corrona RA
registry, we compared the clinical effectiveness
of TCZ monotherapy with that of TNFis with
varying dose ranges of MTX in patients with
moderate to high disease activity and prior
TNFi exposure seen in routine clinical prac-
tice. Patients who initiated a TNFi ? MTX
were grouped into four cohorts by weekly
Fig. 2 Differences in mean change from baseline in CDAI
at 6 months, TCZ monotherapy vs. TNFi ? MTX.
aAdjusted for age, sex, race (white vs. nonwhite), disabled,
retired, baseline CDAI, baseline modiﬁed Health Assess-
ment Questionnaire, baseline patient pain, baseline
prednisone use/dose, baseline body mass index, prior
biologic use, prior TNFi use, and American College of
Rheumatology functional class. CDAI, Clinical Disease
Activity Index; mono, monotherapy; MTX, methotrexate;
TCZ, tocilizumab; TNFi, tumor necrosis factor inhibitor
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MTX dose: B 10 mg;[ 10 to B 15 mg;[15
to B 20 mg; and[20 mg. To minimize selec-
tion bias, study outcomes were compared
between patients receiving TCZ monotherapy
and each TNFi ? MTX group in trimmed popu-
lations excluding patients outside the PS distri-
bution overlap and in stratified-matched
populations in which patients were stratified by
the number of prior TNFi and matched based on
the PS. Treatment with either TCZmonotherapy
or a TNFi ? MTX was associated with improve-
ment in RA disease activity, and outcomes were
comparable between patients who initiated TCZ
monotherapy and those who initiated a
TNFi ? MTX, regardless of MTX dose, over
6 months. In adjusted analyses of both the
trimmed and stratified-matched populations,
there were no significant differences in the
improvement of CDAI or mHAQ or the likeli-
hood of achieving LDA (CDAI B 10) or mACR
responses at 6 months between the TCZ
monotherapy and TNFi ? MTX groups.
Randomized clinical trials have demon-
strated that TCZ monotherapy is more effective
than MTX monotherapy or monotherapy with
the TNFi adalimumab for the improvement of
RA disease activity [23, 24]. However, there are
limited data available regarding the effective-
ness of TCZ monotherapy compared with
TNFi ? MTX. Additionally, these trials exclu-
ded patients with prior biologic exposure or
patients with an inadequate response to a prior
Fig. 3 ORs for achievement of LDA (CDAI B 10) at
6 months, TCZ monotherapy vs. TNFi ? MTX. aAd-
justed for age, sex, race (white vs. nonwhite), disabled,
retired, baseline CDAI, baseline modiﬁed Health Assess-
ment Questionnaire, baseline patient pain, baseline pred-
nisone use/dose, baseline body mass index, prior biologic
use, prior TNFi use, and American College of Rheuma-
tology functional class. CDAI, Clinical Disease Activity
Index; LDA, low disease activity; mono, monotherapy;
MTX, methotrexate; OR, odds ratio; TCZ, tocilizumab;
TNFi, tumor necrosis factor inhibitor
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Fig. 4 ORs for achievement of mACR20 and mACR50
responses at 6 months, TCZ monotherapy vs. TNFi ?
MTX. aAdjusted for age, sex, race (white vs. nonwhite),
disabled, retired, baseline Clinical Disease Activity Index,
baseline modiﬁed Health Assessment Questionnaire, base-
line patient pain, baseline prednisone use/dose, baseline
body mass index, prior biologic use, prior TNFi use, and
ACR functional class. mACR, modiﬁed American College
of Rheumatology response; mono, monotherapy; MTX,
methotrexate; OR, odds ratio; TCZ, tocilizumab; TNFi,
tumor necrosis factor inhibitor
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TNFi; comparative effectiveness studies of TCZ
monotherapy vs. TNFi ? MTX in patients with
prior biologic experience are lacking.
A recent analysis from the TOCERRA collab-
oration of European registries compared the
effectiveness of TCZ vs. TNFis as monotherapy
or in combination with csDMARDs in biologic-
experienced patients with RA [25]. No signifi-
cant differences were observed in change in
CDAI score at 1 year among patients who initi-
ated TNFi monotherapy (mean change, - 3.54),
TNFi ? csDMARDs (- 3.34), TCZ monotherapy
(- 3.58) or TCZ ? csDMARDs (- 3.68) [25]. In
addition, no significant differences were
observed in the proportion of patients who
achieved CDAI LDA at 1 year among the treat-
ment groups [25]. To our knowledge, ours is the
first US study to evaluate the comparative
effectiveness of switching to a TNFi with vary-
ing dose ranges of MTX vs. switching to
monotherapy with a biologic with a different
MOA after an inadequate response to a TNFi in a
population of patients seen in routine clinical
practice. Consistent with the results from
TOCERRA, treatment with TCZ monotherapy or
a TNFi ? MTX resulted in comparable changes
in CDAI scores and rates of achievement of LDA
at 6 months in our US study population. Our
study also found no evidence of a difference in
the effectiveness of TCZ monotherapy or a
TNFi ? MTX with respect to improvement in
mHAQ and achievement of mACR20/50
responses. Thus, our findings support those
from the TOCERRA registry study and provide
Fig. 5 Differences in mean change from baseline in
mHAQ at 6 months, TCZ monotherapy vs. TNFi ?
MTX. aAdjusted for age, sex, race (white vs. nonwhite),
disabled, retired, baseline Clinical Disease Activity Index,
baseline mHAQ, baseline patient pain, baseline prednisone
use/dose, baseline body mass index, prior biologic use,
prior TNFi use, and American College of Rheumatology
functional class. mHAQ, modiﬁed Health Assessment
Questionnaire; mono, monotherapy; MTX, methotrexate;
TCZ, tocilizumab; TNFi, tumor necrosis factor inhibitor
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further evidence for the comparable effective-
ness of TCZ monotherapy with that of TNFi ?
MTX in patients previously treated with
biologics.
We evaluated TNFis administered with vari-
ous dose ranges of MTX and observed compa-
rable disease outcomes at 6 months in patients
treated with TCZ monotherapy vs. those treated
with a TNFi ? MTX, regardless of MTX dose.
Comparable effectiveness of increasing MTX
doses in combination with TNFis has been
observed in randomized clinical trials. The
MUSICA trial assessed disease outcomes in
patients with RA treated with adalimumab plus
MTX 7.5 mg/week or 20 mg/week; no signifi-
cant differences were observed in the propor-
tions of patients who achieved ACR20/50/70
responses or CDAI LDA at week 24 between the
MTX dose groups [26]. Similarly, a pooled
analysis of the TEMPO and COMET trials
found no significant differences in the rates of
DAS28 LDA and remission and ACR20/50/70
responses over 6, 12, and 24 months among
biologic-naı¨ve patients treated with etanercept
plus MTX\ 10 mg/week, 10–17.5 mg/week,
or[17.5 mg/week [27]. Additionally, results
from the TOCERRA registry study showed sim-
ilar rates of CDAI remission and LDA between
patients who received TCZ monotherapy and
patients who received a TNFi with MTX across
MTX doses [25]. The comparable effectiveness
of TCZ monotherapy vs. TNFis ? MTX across
various MTX dose ranges observed in our study
reflect the observations of these previous
studies.
The results of this study have important
clinical relevance to practicing rheumatologists.
Comparative effectiveness studies of TNFis vs.
non-TNFi biologics are necessary to help guide
decision-making when selecting a biologic
therapy for patients with prior TNFi exposure.
Additionally, comparative effectiveness studies
of TNFis ? MTX vs. monotherapy with biolog-
ics with different MOAs are needed to ensure
the best clinical outcomes in patients for whom
MTX use is contraindicated. In the absence of
head-to-head clinical trials, observational stud-
ies can provide important information for
clinicians when deciding which biologic to
prescribe a patient with prior TNFi exposure.
This study showed that TCZ monotherapy and
TNFi ? MTX were associated with substantial
and comparable clinical improvement in real-
world clinical practice. Thus, factors such as
individual patient characteristics, pharmacy
benefit plans, and patient preferences will likely
inform individual biologic prescription choices.
This study has several strengths. This all-
comers study design recruited participants from
multiple rheumatology centers across the Uni-
ted States, resulting in a range of patients with
real-world disease activity and comorbidities
not typically seen in randomized controlled
trials. The prospective, observational nature of
this study allowed us to compare the efficacy of
TCZ monotherapy with that of TNFi ? MTX in
routine management of RA. Patients initiating a
TNFi were stratified by concomitant MTX dose
to account for the effect of MTX on disease
activity outcomes. Patients were included in the
analyses regardless of switching or discontinu-
ing their initial biologic, which allowed a more
conservative estimate of effectiveness [28].
Comparative effectiveness was broadly exam-
ined using multiple assessments, including
CDAI, mACR response, and mHAQ.
This study also has some limitations. A gen-
eral limitation of real-world observational
studies is the concern that patients enrolled in
registries may not be representative of patients
observed elsewhere in general practice. How-
ever, a previous study found that Medicare
patients in the Corrona registry were similar to
the national US Medicare RA population in
terms of demographic characteristics and
comorbid conditions, suggesting that data from
patients in Corrona may be generalizable to the
population of patients with RA in the United
States [19]. Another general limitation of real-
world observational studies is the potential for
bias because physicians prescribe therapies
based on a patient’s profile and treatment
selection is not random. To address this limita-
tion, analyses were conducted in two popula-
tions: a trimmed population excluding patients
outside the PS overlap (not on common sup-
port) and a population of patients stratified by
prior TNFi use and matched on PS. However,
this method does not address unmeasured
confounding variables. Reasons for
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discontinuation of prior TNFis were not avail-
able for all patients; thus, sensitivity analyses
were not performed based on reasons for dis-
continuation of prior TNFis, although other
studies have shown that this may influence
treatment response [29]. For example, it is pos-
sible that the occurrence of a serious adverse
event may influence the likelihood of switching
from a TNFi to a biologic with a different MOA.
Additionally, small sample sizes prohibited the
evaluation of individual TNFis; rather, TNFis
were pooled and analyzed as a group. Thus, no
conclusions can be drawn regarding differences
in the effectiveness of TCZ monotherapy vs.
specific TNFis ? MTX. Choice of specific TNFi
and patients’ treatment history may affect the
impact of MTX dose on disease outcomes in
patients treated with TNFi ? MTX. Finally, fol-
low-up time was limited to 6 months; longer
follow-up is necessary to assess the long-term
effectiveness of switching from a TNFi to TCZ
monotherapy vs. a subsequent TNFi ? MTX.
CONCLUSIONS
This observational, real-world study of US
patients with RA showed no evidence of a dif-
ference in the efficacy of TCZ monotherapy
compared with TNFi ? MTX, regardless of MTX
dose, for improving RA disease activity in
patients with prior TNFi exposure. There was no
evidence of differences in clinical outcomes at
6 months, including improvement in CDAI,
achievement of LDA, achievement of mACR20
or mACR50 response, and improvement in
mHAQ, between patients who switched to TCZ
monotherapy and those who switched to a
subsequent TNFi ? MTX. These results suggest
that, in clinical practice, TCZ monotherapy may
be an effective treatment option for patients
with RA who have been previously treated with
TNFis.
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